MXPA05013349A - Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. - Google Patents
Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.Info
- Publication number
- MXPA05013349A MXPA05013349A MXPA05013349A MXPA05013349A MXPA05013349A MX PA05013349 A MXPA05013349 A MX PA05013349A MX PA05013349 A MXPA05013349 A MX PA05013349A MX PA05013349 A MXPA05013349 A MX PA05013349A MX PA05013349 A MXPA05013349 A MX PA05013349A
- Authority
- MX
- Mexico
- Prior art keywords
- raf kinase
- kinase inhibitors
- aminopyrimidine derivatives
- compounds
- phenyl radical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Esta solicitud da a conocer compuestos que inhiben la quinasa Raf, que tienen la formula (I) (ver formula (I)): en donde R1 es un radical de fenilo o un radical de heterorarilo; y R2 es un radical de fenilo; o un N-oxido o una sal farmaceuticamente aceptable de los mismos. Los compuestos son utiles para el tratamiento de enfermedades proliferativas, tales como cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47870903P | 2003-06-13 | 2003-06-13 | |
PCT/EP2004/006317 WO2004110452A1 (en) | 2003-06-13 | 2004-06-11 | 2-aminopyrimidine derivatives as raf kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05013349A true MXPA05013349A (es) | 2006-03-09 |
Family
ID=33551850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05013349A MXPA05013349A (es) | 2003-06-13 | 2004-06-11 | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060293340A1 (es) |
EP (1) | EP1635835B1 (es) |
JP (1) | JP2006527230A (es) |
CN (1) | CN1805748B (es) |
AT (1) | ATE454152T1 (es) |
AU (1) | AU2004246800B2 (es) |
BR (1) | BRPI0411365A (es) |
CA (1) | CA2529090A1 (es) |
DE (1) | DE602004024988D1 (es) |
ES (1) | ES2338557T3 (es) |
MX (1) | MXPA05013349A (es) |
PL (1) | PL1635835T3 (es) |
PT (1) | PT1635835E (es) |
WO (1) | WO2004110452A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7939541B2 (en) * | 2004-09-09 | 2011-05-10 | Natco Pharma Limited | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
EP1786799B1 (en) * | 2004-09-09 | 2012-07-04 | Natco Pharma Limited | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
CN1939910A (zh) * | 2004-12-31 | 2007-04-04 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
KR20070106036A (ko) * | 2005-02-25 | 2007-10-31 | 노파르티스 아게 | Bcr-abl 및 raf 억제제의 제약 조합물 |
KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
US20100216791A1 (en) * | 2006-08-17 | 2010-08-26 | Astrazeneca | Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors |
KR101420892B1 (ko) | 2006-11-16 | 2014-07-17 | 에프.아이.에스. 파브리카 이탈리아나 신테티치 에스.피.에이. | 이마티닙 및 그들의 중간체 및 그 제조방법 |
EA019524B1 (ru) * | 2007-05-04 | 2014-04-30 | Айрм Ллк | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR |
JP5710251B2 (ja) * | 2007-06-07 | 2015-04-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規ヘテロ環化合物およびその使用 |
JP5559043B2 (ja) | 2007-06-07 | 2014-07-23 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 新規ヘテロ環化合物およびその使用 |
CA2709257C (en) | 2007-12-19 | 2016-12-13 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
CA2716949A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
EP2265609B1 (en) * | 2008-02-29 | 2012-09-05 | Array Biopharma, Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
PE20091561A1 (es) * | 2008-02-29 | 2009-10-30 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para su uso |
WO2009111279A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
SG178279A1 (en) | 2009-08-05 | 2012-03-29 | Intra Cellular Therapies Inc | Novel regulatory proteins and inhibitors |
EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
NZ706154A (en) | 2010-02-01 | 2016-09-30 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
JP2013526513A (ja) * | 2010-05-11 | 2013-06-24 | クリサニ バイオサイエンシーズ プライベート リミッテッド | 4,6−ジベンジルアミン−2−メチル−ピリミジン誘導体、および癌治療のためのそれらの使用 |
US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
US8551479B2 (en) * | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
EA201390740A1 (ru) * | 2010-11-19 | 2013-12-30 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Способ лечения с использованием ингибитора braf |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
US9828370B2 (en) * | 2015-04-23 | 2017-11-28 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
CN108864060A (zh) * | 2018-06-03 | 2018-11-23 | 刘思良 | 一种重氮类衍生物及其在癌症治疗中的应用 |
CN108484587A (zh) * | 2018-06-03 | 2018-09-04 | 刘思良 | 一种Raf激酶抑制剂及其在癌症治疗中的应用 |
CN108610336A (zh) * | 2018-06-03 | 2018-10-02 | 刘思良 | 一种重氮类衍生物及其在癌症治疗中的应用 |
CN108586439A (zh) * | 2018-06-03 | 2018-09-28 | 刘思良 | 一种Raf激酶抑制剂及其在癌症治疗中的应用 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2023150197A1 (en) * | 2022-02-03 | 2023-08-10 | Nexys Therapeutics, Inc. | Aryl hydrocarbon receptor agonists and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225528B (es) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
UA71555C2 (en) * | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
GB9924092D0 (en) * | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
EP1395261B1 (en) * | 2001-05-16 | 2006-06-28 | GPC Biotech AG | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
GB0121488D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0201508D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
GB0202873D0 (en) * | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
US20040005641A1 (en) * | 2002-02-15 | 2004-01-08 | Michael Burnet | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
ES2337995T3 (es) * | 2002-06-28 | 2010-05-03 | Nippon Shinyaku Co., Ltd. | Derivado de amida. |
US7144911B2 (en) * | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
GB2398565A (en) * | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
-
2004
- 2004-06-11 CA CA002529090A patent/CA2529090A1/en not_active Abandoned
- 2004-06-11 DE DE602004024988T patent/DE602004024988D1/de not_active Expired - Lifetime
- 2004-06-11 BR BRPI0411365-9A patent/BRPI0411365A/pt not_active IP Right Cessation
- 2004-06-11 PL PL04739809T patent/PL1635835T3/pl unknown
- 2004-06-11 EP EP04739809A patent/EP1635835B1/en not_active Expired - Lifetime
- 2004-06-11 JP JP2006515898A patent/JP2006527230A/ja active Pending
- 2004-06-11 PT PT04739809T patent/PT1635835E/pt unknown
- 2004-06-11 US US10/560,352 patent/US20060293340A1/en not_active Abandoned
- 2004-06-11 CN CN2004800163287A patent/CN1805748B/zh not_active Expired - Fee Related
- 2004-06-11 AT AT04739809T patent/ATE454152T1/de not_active IP Right Cessation
- 2004-06-11 MX MXPA05013349A patent/MXPA05013349A/es active IP Right Grant
- 2004-06-11 WO PCT/EP2004/006317 patent/WO2004110452A1/en active Application Filing
- 2004-06-11 AU AU2004246800A patent/AU2004246800B2/en not_active Ceased
- 2004-06-11 ES ES04739809T patent/ES2338557T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
BRPI0411365A (pt) | 2006-07-25 |
CN1805748B (zh) | 2010-05-26 |
EP1635835B1 (en) | 2010-01-06 |
US20060293340A1 (en) | 2006-12-28 |
CN1805748A (zh) | 2006-07-19 |
ES2338557T3 (es) | 2010-05-10 |
WO2004110452A1 (en) | 2004-12-23 |
DE602004024988D1 (de) | 2010-02-25 |
PT1635835E (pt) | 2010-03-17 |
AU2004246800A1 (en) | 2004-12-23 |
EP1635835A1 (en) | 2006-03-22 |
CA2529090A1 (en) | 2004-12-23 |
JP2006527230A (ja) | 2006-11-30 |
AU2004246800B2 (en) | 2008-12-04 |
PL1635835T3 (pl) | 2010-06-30 |
ATE454152T1 (de) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
WO2003051366A3 (en) | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer | |
NO20090580L (no) | Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
UA93351C2 (uk) | Похідні фталазіну як інгібітори parp | |
HK1093159A1 (en) | Monocyclic heterocycles as kinase inhibitors | |
RS20050609A (en) | Pyrazolopyridine derivatives | |
TW200732339A (en) | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | |
CY1111083T1 (el) | Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38 | |
MXPA05008878A (es) | Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso. | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
EP1631548A4 (en) | INHIBITORS OF AKT ACTIVITY | |
HK1080470A1 (en) | Heterocyclic compounds | |
GEP20084367B (en) | Diazepinoindole derivatives as kinase inhibitors | |
GB0112348D0 (en) | Compounds | |
EP2205088A4 (en) | NAPHTHALIN-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | |
WO2005021544A3 (en) | N3-substituted imidazopyridine-derivatives as c-kit inhibitors | |
AU2006273692A8 (en) | 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
NO20044526L (no) | Hemisterlinderivater og anvendelser derav | |
WO2003028721A3 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
TW200628153A (en) | Novel compounds | |
GB0308201D0 (en) | Novel compounds | |
WO2005021510A3 (en) | Benzimidazole c-2 heterocycles as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |